Ipamorelin research focuses on GHSR receptor pharmacology, pituitary growth-hormone release and endocrine selectivity, first characterised in the literature as the original selective secretagogue in its class (Learn more). It is frequently compared with earlier growth-hormone-releasing peptides such as GHRP-6 to examine differences in receptor selectivity and secondary endocrine signalling. This makes it useful in mechanistic studies of the ghrelin-growth-hormone axis, often studied alongside CJC-1295 with DAC.
Born from GHRP-1: the Novo Nordisk chemistry programme
Ipamorelin was the standout of a large medicinal-chemistry effort at Novo Nordisk in Denmark, where chemists took the heptapeptide GHRP-1 and cut out its central Ala-Trp pair, then refined the shortened series until one pentapeptide stood out. Inside the company it carried the code NNC 26-0161, and that label still turns up in older pharmacology papers.
The same team kept going. A 1998 paper in the Journal of Medicinal Chemistry used Ipamorelin as the parent for a new family of smaller molecules, built with a benzoic-acid fragment and N-methylated backbones in a push towards oral activity; one of them, the tetrapeptide NNC 26-0235, reached about 10% oral bioavailability in dogs. In rats, Ipamorelin’s plasma clearance was about five times lower than that of GHRP-6.
Potency, efficacy and a six-hormone panel
The founding Ipamorelin paper measured far more than growth hormone. In primary rat pituitary cells it released GH at an EC50 of about 1.3 nmol/L, close to GHRP-6 at 2.2 nmol/L, reaching around 85% of GHRP-6’s maximum. In conscious pigs the half-maximal dose was about 2.3 nmol/kg. GHRP-2 behaved differently in the same pigs: more potent, at roughly 0.6 nmol/kg, but with a lower ceiling on the GH peak.
The pig work then screened six other pituitary and adrenal hormones. FSH, LH, prolactin and TSH stayed flat with every secretagogue tested, so prolactin was not what separated the compounds in that model. The dividing line was the stress axis, where GHRP-2 and GHRP-6 pushed ACTH and cortisol up and Ipamorelin did not. Prolactin selectivity is worth checking species by species, though: macimorelin, a later oral ghrelin-receptor agonist, raised prolactin in a study of healthy volunteers while leaving ACTH and cortisol unchanged.
The ghrelin receptor: a switch never fully off
GHSR-1a, the receptor Ipamorelin binds, has an unusual habit. Working in transfected cells, Birgitte Holst and colleagues, with Novo Nordisk chemist Michael Ankersen among the authors, showed in 2003 that it signals strongly with no ligand present at all. A modified substance P peptide, long used as a weak ghrelin-receptor blocker, turned out to be a potent inverse agonist that silenced this background signal. The body has its own brake too: LEAP2, a peptide made in the liver and gut, is now recognised as a natural GHSR antagonist.
That high baseline means an agonist such as Ipamorelin adds to a receptor that is already partly active, something to keep in mind when reading dose-response data. The receptor also reaches well beyond the pituitary. In GH-deficient lit/lit mice, Ipamorelin still increased fat-pad weight relative to body weight, and in GH-intact mice secretagogue treatment raised food intake and serum leptin, pointing to GH-independent effects that may run partly through extra feeding.
From pituitary to bowel: the Helsinn ileus programme
Ghrelin speeds up the gut, which gave Ipamorelin a second career. Sapphire Therapeutics, a New Jersey company, developed an intravenous form for postoperative ileus, the stalled bowel that can follow abdominal surgery, and Helsinn bought Sapphire in early 2009, gaining a second ghrelin-receptor agonist, anamorelin, in the same deal and renaming the business Helsinn Therapeutics (U.S.).
Rat data looked encouraging. After laparotomy and handling of the intestine, Ipamorelin shortened the time to the first bowel movement, and in a later study it cut the share of a test meal still left in the stomach from 78% to 52%, while restoring contractions in isolated gastric muscle. Two Phase II trials followed: a study that enrolled 117 patients, in which median time to the first tolerated meal was 25.3 hours against 32.6 hours on placebo (p = 0.15), and a larger dose-finding study of 320 patients completed in 2014. Development then stopped, reportedly for lack of efficacy. Anamorelin went further and was approved in Japan in 2021 as Adlumiz for cancer cachexia, a regulatory fact about that separate molecule only.
Repeated exposure and the desensitisation question
Receptors that are stimulated again and again often respond less, and the growth-hormone secretagogue class is no exception: in one rat study, six weeks of the oral agonist MK-677 abolished its GH response, alongside a rise in hypothalamic somatostatin. So how does Ipamorelin behave?
The human pharmacokinetic study by Gobburu and colleagues gives a first clue. Healthy men received 15-minute infusions at five escalating levels, eight per level. Ipamorelin had a terminal half-life of about two hours, yet GH came in a single burst peaking at around 40 minutes and then fell to negligible levels at every dose, which the authors modelled as release over a fixed window. In young female rats given Ipamorelin for 21 days, pituitary cells kept responding: when cultured and challenged afresh with Ipamorelin, GHRP-6 or GHRH, only cells from the Ipamorelin-treated animals raised their GH content, and secretory granule density had risen. Long-term human data on this question remain absent.
